Mitozolomide
From WikiMD's WELLNESSPEDIA
| Mitozolomide | |
|---|---|
| Mitozolomide.svg | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 85622-95-3 |
| PubChem | 71766 |
| DrugBank | |
| ChemSpider | 64805 |
| KEGG | |
Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.
Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]
References[edit]
- ↑ "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide".Cancer Gene Ther.February 2000;7(2)
- 233–9.doi:10.1038/sj.cgt.7700120.PMID:10770631.Full text.
- ↑ "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)".Br J Cancer.February 1992;65(2)
- 287–91.doi:10.1038/bjc.1992.57.PMID:1739631.PMC:1977719.
-
Mitozolomide